Fig. 1 · Structure

Documents & Downloads

PAC-1

Cat. No. A11090 CAS 315183-21-2

Caspase activator

PAC-1 is an activator of procaspase-3 induces apoptosis in cancer cells with EC50 of 2.08 μM.

In Stock

Publications for PAC-1

1 publication citing this product

  1. Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PAC-1 binds zinc and relieves zinc-mediated inhibition of procaspase-3 in biochemical systems. Solution measurements reported 1:1 zinc binding and a Kd of 42 nM; this metal-binding constant is distinct from cellular potency. Mutant enzyme/substrate experiments supported zinc-dependent procaspase processing, with PAC-1a serving as a negative control. [1]

PAC-1 activity depends on assay conditions: metal removal abolished its activating effect, and high PAC-1 concentrations inhibited caspase-3/procaspase-3 activity. Assay buffer and zinc content therefore matter when interpreting PAC-1 responses. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Procaspase-3 EC50 0.22 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 2.51 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 25874341]
B16-F10 IC50 > 100 μM Activation of procaspase-3-mediated human B16-F10 cell death after 24 hrs by MTS/PMS assay [PMID: 16936720]
BT-549 IC50 14.3 μM Cytotoxicity against Smac mimetic-resistant human BT549 cells assessed as growth inhibition after 24 hrs by CellTiter-Glo assay [PMID: 27578248]
Cancer cell lines IC50 0.003 μM Cytotoxicity against human colon cancer cells after 24 hrs by MTS/PMS assay [PMID: 16936720]
Colon cell IC50 5.02 μM Cytotoxicity against human colon cells after 24 hrs by MTS/PMS assay [PMID: 16936720]
EL4 IC50 6.5 μM Cytotoxicity against mouse EL4 cells assessed as cell death after 72 hrs by sulforhodamine B assay [PMID: 25856364]
HL-60 IC50 0.92 μM Activation of procaspase-3-mediated human HL60 cell death after 72 hrs by MTS/PMS assay [PMID: 16936720]
Hs-578T IC50 > 100 μM Activation of procaspase-3-mediated human Hs 578T cell death after 24 hrs by MTS/PMS assay [PMID: 16936720]
HT-29 IC50 0.83 μM Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay [PMID: 26897090]
HT-29 IC50 0.83 μM Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay [PMID: 23838381]
HT-29 IC50 0.97 μM Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 23059545]
HT-29 IC50 1.02 μM Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay [PMID: 25874341]
HT-29 IC50 1.36 μM Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay [PMID: 25171780]
Jurkat IC50 4.4 μM Cytotoxicity against human Jurkat cells assessed as cell death after 72 hrs by sulforhodamine B assay [PMID: 25856364]
MCF-10A IC50 3.2 μM Activation of procaspase-3-mediated human MCF-10A cell death after 72 hrs by MTS/PMS assay [PMID: 16936720]
MCF7 IC50 > 40 μM Antiproliferative activity against human MCF7 cells after 24 hrs by CCK-8 assay [PMID: 31015910]
MCF7 IC50 > 75 μM Activation of procaspase-3 in human MCF-7 cells assessed as cell death after 72 hrs [PMID: 16936720]
MDA-MB-231 IC50 3.2 μM Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay [PMID: 25874341]
MDA-MB-231 IC50 4.6 μM Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay [PMID: 26897090]
MDA-MB-231 IC50 4.6 μM Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay [PMID: 23838381]

20 records · Scroll to view more

PAC-1 Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of PAC-1 from 3 published references. In vitro models include PAC-1 and ZnSO4 in HEPES/KNO3 buffer; purified caspase-3 and procaspase-3 peptide-substrate assays.

PAC-1 In Vitro Studies

In a six-day ATP-based endometrial cancer screen, the PAC-1 response-curve AUC was higher in REME9 and REME16 tumor organoids than in AN3 CA and RL95-2 cells, indicating lower sensitivity in those organoid models. The paper lists AdooQ BioScience as the PAC-1 supplier. Exact PAC-1 IC50 values were not extracted from this graphical screen. [2]

PAC-1–zinc binding in solution

Biochemical assay · PAC-1 and ZnSO4 in HEPES/KNO3 buffer [1]

Spectrophotometric continuous-variation analysis supported 1:1 zinc binding with a reported Kd of 42 nM. The paper also reports 55 nM by EGTA competition; these are metal-binding constants, not cellular potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAC-1–Zn2+ affinityKd 42 nM[1]
Independent metal-binding affinity estimateKd 55 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
PAC-1 + ZnSO4 total concentration 50 μM in continuous variations; PAC-1 50 μM for spectral titration.
Method
UV-visible absorbance; normalized absorbance at 410 nm; independent EGTA competition.
Vehicle
DMSO stocks diluted into aqueous buffer.
Reported limits
Figure 9a caption states pH 7.2, whereas Methods buffer A states pH 7.4; exact assay pH remains discrepant. A single pH is not assigned here.
Methods and source locations

Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1

Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.

Figure 9 and Results PAC-1 binds tightly to Zn2+; Methods Zinc Titration, Continuous Variations Method and EGTA Competition Titration

PAC-1–Zn2+ affinity: Continuous variations; 1:1 stoichiometry; Figure 9 error bars denote standard deviation. — Figure 9b; Results PAC-1 binds tightly to Zn2+

Independent metal-binding affinity estimate: EGTA competition, absorbance at 410 nm; main-text reported result, not a curve-derived estimate. — Results PAC-1 binds tightly to Zn2+, final paragraph; Methods EGTA Competition Titration

Buffer and zinc dependence of PAC-1 enzyme activity

Biochemical assay · Purified caspase-3 and procaspase-3 peptide-substrate assays [1]

PAC-1 increased enzyme activity under zinc-inhibited conditions. Removing inhibitory metals eliminated the activating effect; high PAC-1 concentrations inhibited activity. These results do not establish a universal cellular mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Effect of PAC-1 after buffer metal removalQualitative activity No activating effect after Chelex treatment; slight inhibition described.[1]
Enzyme activity with zinc versus zinc-free referenceRelative activity 40–60% of maximal rate reported across the enzyme assays; high compound concentrations inhibited activity.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 1: 50 μM PAC-1; Figure 4: 0.025–100 μM PAC-1, with or without 5 μM ZnSO4 (panels a–b).
Exposure duration
2 h at 37°C before substrate addition; absorbance monitored for 1 h.
Method
Ac-DEVD-pNA hydrolysis at 405 nm; buffer and no-zinc controls.
Vehicle
DMSO matched across wells; activity method specifies never above 5%.
Reported limits
No exact activation EC50 adopted. Figure 4c has a zinc-dose discrepancy between caption and plotted label and is not used for a dose-specific claim.
Methods and source locations

Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1

Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.

Figures 1c–d and 4a–b; Results buffer dependence, metal removal and dose response; Methods Buffer Analysis and Assay of Procaspase-3/-7 and Caspase-3/-7 Activity

Effect of PAC-1 after buffer metal removal: 500 nM procaspase-3; 50 μM PAC-1 versus vehicle; Ac-DEVD-pNA 200 μM. — Figure 1d; Results Metal removal abolishes the activating effect of PAC-1; Methods Buffer Analysis

Enzyme activity with zinc versus zinc-free reference: Dose response; Figures 4a–b show 500 nM caspase-3/procaspase-3 with 5 μM ZnSO4. Representative of three trials; methods describe triplicate points and at least three repeats. — Figure 4a–b and caption; Results dose response; Discussion final paragraph

Orthogonal validation of zinc-dependent procaspase processing

Biochemical assay · Uncleavable procaspase-3(D9A/D28A/D175A) enzyme and catalytically inactive procaspase-3(C163A) substrate [1]

Zinc inhibited production of p17/p12 fragments; PAC-1 restored processing, whereas PAC-1a did not. Separating enzyme and substrate roles supports the biochemical zymogen mechanism without claiming cell-level specificity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Zinc-inhibited cleavage of procaspase substrateQualitative proteolysis PAC-1 restored processing; PAC-1a did not.[1]

Literature-Reported Treatment Conditions

Treatment concentration
PAC-1 50 μM; ZnSO4 100 μM; D3A enzyme 10 μM; C163A substrate 50 μM.
Exposure duration
0, 6 and 12 h at 37°C.
Method
Western blot detection of p17/p12 processing products.
Vehicle
DMSO compound stock; no-zinc and zinc-only controls.
Co-treatment
PAC-1 plus ZnSO4; parallel PAC-1a negative control.
Reported limits
Qualitative blot outcome; no densitometric percentage or catalytic constant adopted.
Methods and source locations

Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1

Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.

Figure 6; Results PAC-1 induces procaspase-3 automaturation; Methods Western blot analysis of procaspase-3 activation

Zinc-inhibited cleavage of procaspase substrate: Figure 6 lanes 1–3 no zinc, 4–6 zinc, 7–9 zinc + PAC-1, 10–12 zinc + PAC-1a. Methods report four repeats on two protein batches. — Figure 6 and caption; Methods Western blot analysis of procaspase-3 activation

PAC-1 in an endometrial organoid drug screen

Cell-based study · REME9 and REME16 patient-derived endometrial tumor organoids, compared with AN3 CA and RL95-2 cell lines [2]

The PAC-1 bars in the multi-agent screen showed higher growth-response AUC in the organoids than in either conventional cell line, consistent with lower sensitivity in the organoid models. No exact PAC-1 AUC or IC50 was transcribed from the graph.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Growth inhibition response integrated over tested concentrationsQualitative AUC comparison REME9 and REME16 PAC-1 AUC bars exceed those for AN3 CA and RL95-2.[2]

Literature-Reported Treatment Conditions

Exposure duration
144 h (6 days) after treatment.
Method
384-well ATP-based CellTiter-Glo 3D viability assay; AUC calculated from growth-inhibition curves.
Vehicle
DMSO control; methods specify a maximum of 0.1%.
Reported limits
Concentration range is inconsistent: 384-well Methods state 1.0 nM–20 μM (ten dilutions), while Figure 6 caption states 0.1–20 μM. Exact exposure grid is unresolved. Figure reports means of triplicate experiments without exact PAC-1 numerical labels.
Methods and source locations

Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1

Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.

Table II PAC-1 row; Figure 6; Methods Compounds, Cell culture and Growth inhibition assays using multi-well plates; Results Evaluation of anticancer agents using F-PDOs

Growth inhibition response integrated over tested concentrations: Viewed Figure 6; higher response-curve AUC indicates lower growth inhibition. Figure caption: mean of triplicate experiments. — Figure 6 PAC-1 row and caption; Results Evaluation of anticancer agents using F-PDOs

PAC-1 In Vivo Studies

In intracranial 9L glioma-bearing rats, ten oral PAC-1 doses at 50 mg/kg increased median survival from 11.5 to 20 days (n=8 per group; p<0.001). A separate five-dose schedule did not improve survival (13.5 versus 14.5 days; p=0.75). Sequential PAC-1 followed by temozolomide increased median survival to 28 days versus 20 days with temozolomide alone (p=0.007). These outcomes depend on the tested schedule and combination. [3]

Ten-dose oral PAC-1 in intracranial 9L glioma

Animal study · Randomized female F344 rats with syngeneic intracranial 9L glioma; n=8 per group. [3]

A ten-dose PAC-1 schedule increased median survival from 11.5 to 20 days compared with untreated controls. This preclinical result is specific to its model and schedule.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival after ten-dose oral PAC-1Median survival 20 days (PAC-1) versus 11.5 days (control); p<0.001; n=8 per group.[3]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PAC-1
50 mg/kg
Untreated rats.Median survival 20 days versus 11.5 days; p<0.001; n=8 per group.[3]
Untreated controlReference group.Median survival 11.5 days; n=8.[3]
PAC-1
Model: Female F344 rats with intracranial syngeneic 9L glioma; 150–200 g; n=8 per group.
Route: Oral
Frequency: Once daily on treatment days
Treatment course: Days 5–9 and 12–16 after implantation; 10 doses.
Vehicle: Aqueous suspension.
Reported limits: Main text gives no blinded outcome assessment. No current supplier-lot validation.
Untreated control
Model: Female F344 rats with intracranial syngeneic 9L glioma; 150–200 g; n=8 per group.
Treatment course: Concurrent follow-up.
Reported limits: Main text gives no blinded outcome assessment. No current supplier-lot validation.
Methods and source locations

Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1

Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.

Figure 3A; Results PAC-1 is efficacious in a syngeneic orthotopic glioblastoma rodent model; Methods 9L glioma, syngeneic in F344 rats and Statistical analysis

Survival after ten-dose oral PAC-1: Log-rank comparison; randomized treatment assignment. — Figure 3A caption; Results single-agent efficacy; Methods Statistical analysis

PAC-1 · Figure 3A; Results single-agent efficacy; Methods 9L model

Untreated control · Figure 3A; Methods 9L model

Five-dose PAC-1 alone and sequential PAC-1/TMZ

Animal study · Randomized female F344 rats with intracranial syngeneic 9L glioma; four groups, n=8 each. [3]

Five PAC-1 doses alone did not significantly improve survival. Sequential PAC-1 then temozolomide extended median survival to 28 days versus 20 days with TMZ alone. Combination effects are not assigned to PAC-1 monotherapy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAC-1 monotherapy survival in the five-dose designMedian survival 13.5 days versus 14.5 days (control); p=0.75; n=8 per group.[3]
Sequential PAC-1/TMZ survivalMedian survival 28 days versus 20 days (TMZ); p=0.007; n=8 per group.[3]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Water vehicle controlReference group.Median survival 14.5 days.[3]
PAC-1 alone
50 mg/kg PAC-1
Water vehicle.Median survival 13.5 days versus 14.5 days; p=0.75.[3]
TMZ alone
50 mg/kg TMZ
Water vehicle.Median survival 20 days; p=0.0018 versus control.[3]
Sequential PAC-1 then TMZ
PAC-1 50 mg/kg; TMZ 50 mg/kg
Water and both single-agent groups.Median survival 28 days; p<0.0001 versus control; p=0.007 versus TMZ alone.[3]
Water vehicle control
Model: Female F344 rats with intracranial syngeneic 9L glioma; 150–200 g; n=8 per group.
Treatment course: Concurrent follow-up.
Vehicle: Water.
Reported limits: Main text gives no blinded outcome assessment. No current supplier-lot validation.
PAC-1 alone
Model: Female F344 rats with intracranial syngeneic 9L glioma; 150–200 g; n=8 per group.
Route: Oral
Frequency: Once daily on treatment days
Treatment course: Days 1–5; five doses.
Vehicle: Aqueous suspension.
Reported limits: Main text gives no blinded outcome assessment. No current supplier-lot validation.
TMZ alone
Model: Female F344 rats with intracranial syngeneic 9L glioma; 150–200 g; n=8 per group.
Route: Oral
Frequency: Once daily on treatment days
Treatment course: Days 6–10; five doses.
Reported limits: Main text gives no blinded outcome assessment. No current supplier-lot validation.
Sequential PAC-1 then TMZ
Model: Female F344 rats with intracranial syngeneic 9L glioma; 150–200 g; n=8 per group.
Route: Oral
Frequency: Once daily on treatment days
Treatment course: PAC-1 days 1–5, then TMZ days 6–10.
Vehicle: PAC-1 aqueous suspension; TMZ vehicle not specified in selected main-text methods.
Reported limits: Main text gives no blinded outcome assessment. No current supplier-lot validation.
Methods and source locations

Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1

Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.

Figure 3C; Results PAC-1 synergizes with TMZ in orthotopic glioblastoma rodent models; Methods 9L glioma model and Statistical analysis

PAC-1 monotherapy survival in the five-dose design: Log-rank analysis; separate design from the ten-dose experiment. — Figure 3C; Results PAC-1 synergizes with TMZ

Sequential PAC-1/TMZ survival: Log-rank analysis; combination versus active comparator. — Figure 3C; Results PAC-1 synergizes with TMZ

Water vehicle control · Figure 3C; Results sequential combination

PAC-1 alone · Figure 3C; Results sequential combination

TMZ alone · Figure 3C; Results sequential combination

Sequential PAC-1 then TMZ · Figure 3C; Results sequential combination

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 315183-21-2
Applications Caspase activator
Formula C23H28N4O2
Molecular Weight 392.5
Synonyms first procaspase activating compound
SMILES
C=CCc1cccc(/C=N/NC(=O)CN2CCN(Cc3ccccc3)CC2)c1O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 75 mg/mL (191.09 mM)
Water Insoluble
Ethanol 15 mg/mL (38.21 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PAC-1 Research References

  1. [1] Peterson QP, Goode DR, West DC, et al. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. Journal of molecular biology (2009). PMID: 19281821 DOI: 10.1016/j.jmb.2009.03.003 Source material
  2. [2] Tamura H, Higa A, Hoshi H, et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncology reports (2018). PMID: 29917168 DOI: 10.3892/or.2018.6501 Source material
  3. [3] Joshi AD, Botham RC, Schlein LJ, et al. Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget (2017). PMID: 29113289 DOI: 10.18632/oncotarget.19085 Source material

Publications

1 publication citing this product

  1. Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168

Added to your cart

View Cart Checkout
Loading...